tiprankstipranks
Trinity Biotech Secures Continued U.S. Government Funding for HIV Testing
Company Announcements

Trinity Biotech Secures Continued U.S. Government Funding for HIV Testing

Story Highlights

Maximize Your Portfolio with Data Driven Insights:

  • Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
  • Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio

Trinity Biotech ( (TRIB) ) has issued an announcement.

Trinity Biotech announced a positive update regarding the U.S. government’s funding for HIV testing programs using their rapid HIV tests. On February 1, 2025, the U.S. Department of State confirmed a waiver that ensures continued funding under the President’s Emergency Plan for AIDS Relief, allowing the company to maintain its operations in this critical area.

More about Trinity Biotech

Trinity Biotech is a commercial-stage biotechnology firm based in Ireland, focusing on human diagnostics and diabetes management solutions, including wearable biosensors.

YTD Price Performance: -5.16%

Average Trading Volume: 2,223,627

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $10.23M

For detailed information about TRIB stock, go to TipRanks’ Stock Analysis page.

Related Articles
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App